Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21770659 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL13163960 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29246157 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL1584687 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL7918399 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29231967 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL1604238 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL19181227 | 0.91 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL24739166 | 0.85 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL18923683 | 0.84 | NR1H2 (0.46) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4097110-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | Oncodesign S.A. (FR) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | NR1H2 167/4885SRC 3102/4885UCHL1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.